Table 1.
Characteristics of the included studies
| Ref. | Arm | Sample size | Recruitment period | Study design | Region | CP (A/B/C) | BCLC (A/B/C/D) | Quality |
| Ahmad et al[13] | Y90RE | 24 | 1990-2003 | R | United States | NA | NA | M |
| TACE | 52 | |||||||
| Kooby et al[14] | Y90RE | 27 | 1996-2006 | R | United States | 13/14/0 | NA | H |
| TACE | 44 | 22/22/0 | ||||||
| Carr et al[15] | Y90RE | 99 | 1992-2005 | R | United States | NA | NA | M |
| TACE | 691 | |||||||
| Salem et al[16] | Y90RE | 123 | 1999-2008 | R | United States | 67/54/2 | 43/65/13/2 | H |
| TACE | 122 | 67/53/2 | 47/61/12/2 | |||||
| Lance et al[17] | Y90RE | 38 | 2008-2010 | R | United States | 31/7/0 | NA | H |
| TACE | 35 | 24/11/0 | ||||||
| Moreno-Luna et al[18] | Y90RE | 61 | 1998-2008 | R | United States | 53/8/0 | 12/35/14/0 | H |
| TACE | 55 | 44/11/0 | 23/13/19/0 | |||||
| Pitton et al[19] | Y90RE | 12 | 2010-2012 | RCT | Germany | 10/2/0 | 0/12/0/0 | H |
| TACE | 12 | 9/3/0 | 1/11/0/0 | |||||
| El Fouly et al[20] | Y90RE | 44 | 2009-2011 | R | Egipt/Germany | 37/7/0 | NA | M |
| TACE | 42 | 33/9/0 | ||||||
| Kolligs et al[21] | Y90RE | 13 | 2009-2012 | RCT | Germany/Spain | 9/3/1 | 5/5/3/0 | M |
| TACE | 15 | 9/4/2 | 4/8/3/0 | |||||
| Akinwande et al[22] | Y90RE | 20 | 2007-2013 | R | United States | 7/11/2 | 0/0/20/0 | M |
| TACE | 28 | 14/13/1 | 0/0/28/0 |
CP: Child-Pugh; BCLC: Barcelona Clinic Liver Cancer; Y90RE: Yttrium-90 radioembolization; TACE: Transarterial chemoembolization; R: Retrospective; RCT: Randomized controlled trial; NA: Not available; H: High; M: Moderate.